Scalper1 News
Biotech firm Tekmira Pharmaceuticals vaulted more than 39% in huge volume during afternoon trading on the stock market today after the FDA partially lifted a hold on its drug candidate for treating Ebola. Tekmira’s (TKMR) drug, TKM-Ebola, is in a phase-one clinical trial under a $140 million contract with the Department of Defense. The FDA first put a hold on the trial on July 3, as it wanted more assurance of its safety for the healthy Scalper1 News
Scalper1 News